

Thursday, 17 February 2011 **Revascularisation, ACS, Antithrombotics**

Room Davos

07:30-08:30	Satellite Symposium Biosensors Convincing New Stent Developments Chair: T. Moccetti, Lugano and S. Silber, Munich	
07:30	Stent technology and vascular biology: What do we need?	T. F. Lüscher, Zurich
07:48	Long-term benefits of biodegradable polymer DES in complex populations	P. W. Serruys, Rotterdam
08:06	Future stent generations: What is the promise?	S. Windecker, Berne
08:24	Discussion	

Room Davos

08:30-09:30	Morning Session: Acute Coronary Syndromes I Chair: C. Müller, Basel and M.L. Simoons, Rotterdam	
08:30	Acute coronary syndrome: What did we achieve?	T.F. Lüscher, Zurich
08:50	Imaging vascular inflammation and unstable plaques	P.G. Camici, Milan
09:10	Inflammation as a therapeutic target in ACS	F. Crea, Rome

09:30-10:00 **Coffee**

Room Davos

10:00-11:30	Morning Session: Percutaneous Interventions Chair: C.W. Hamm, Bad Nauheim and T. Moccetti, Lugano	
	New ESC Guidelines on myocardial revascularisation:	
10:00	The interventionalist	W. Wijns, Aalst
10:15	The cardiac surgeon	V. Falk, Zurich
10:30	The fourth revolution in percutaneous coronary revascularisation: Biodegradable drug eluting scaffold	P.W. Serruys, Rotterdam
10:50	Optical coherence tomography for imaging in ACS	S. Windecker, Berne
11:10	Left atrial appendage closure: future role	U. Landmesser, Zurich

11:30-11:45 **Lunch Boxes** (Satellite Symposium)

Room Schwarzhorn

11:45-13:00	Satellite Symposium The Medicines Company Optimising the Antithrombotic Risk-Benefit Profile for Primary PCI Chair: T.F. Lüscher, Zurich and F. Van de Werf, Leuven	
11:45	Introduction	T.F. Lüscher, Zurich
11:50	The burden of disease: outcomes following STEMI	R. Corti, Zurich
12:10	Drivers of mortality following primary PCI: Bleeding, volume and other factors	U. Zeymer, Ludwigshafen
12:30	Antithrombotic therapy in primary PCI: Platelet inhibitors or antithrombins?	C.W. Hamm, Bad Nauheim
12:50	Conclusion	F. Van de Werf, Leuven

13:00-14:15 **Lunch Break**